OKG-0301 for the Treatment of Acute Adenoviral Conjunctivitis

PHASE2UnknownINTERVENTIONAL
Enrollment

219

Participants

Timeline

Start Date

February 11, 2019

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions
Adenoviral Conjunctivitis
Interventions
DRUG

OKG-0301

OKG-0301 is an experimental ophthalmic antiviral and immunomodulatory therapeutic

Trial Locations (6)

2000

Sydney Eye Hospital, Sydney

2640

Albury Eye Clinic, Albury

3002

The Royal Victorian Eye and Ear Hospital, Melbourne E.

5000

The Royal Adelaide Hospital, Adelaide

6009

Lions Eye Institute Day Surgery Centre, Nedlands

7000

Hobart Eye Surgeons, Hobart

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Okogen

INDUSTRY

NCT03856645 - OKG-0301 for the Treatment of Acute Adenoviral Conjunctivitis | Biotech Hunter | Biotech Hunter